Closing prices for 09 October 2026
Next earnings report: 04 November 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Bio-Techne Corp trades on Nasdaq under the ticker TECH. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks TECH has traded between 43.20 $ and 72.69 $. As of 09 October 2026 the price stood 99.22 % of the way from the 52-week low to the high.
Over one year TECH shares rose 19.65 %; over six months they rose 30.46 %. Volatility over 90 days is 36.53 %. Dividends are not included: this is price change only, as of 09 October 2026.
TECH trades at a price-to-earnings ratio of 104, above the sector median of 24.8. Price to sales is 9.4, above the sector median of 3.9. Price to book is 5.4, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 72.46 | 72.52 | 72.44 | 72.46 | 2M |
| 08 October 2026 | 72.56 | 72.58 | 72.43 | 72.45 | 5M |
| 07 October 2026 | 72.43 | 72.55 | 72.43 | 72.53 | 3M |
| 06 October 2026 | 72.58 | 72.61 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Bio-Techne makes the proteins and reagents biological experiments are assembled from.
A researcher needs antibodies, growth factors and assay kits — consumables bought continuously that cost little relative to the experiment itself. A spoiled reagent, however, destroys months of work, so a laboratory is not tempted to economise or change supplier.
The growing part is materials for manufacturing cell and gene therapies: the same proteins, but made to pharmaceutical standards and written into a drug's registration dossier. Such a position is locked in for the medicine's whole life. Risks: funding for science and biotech start-ups, demand in China. A single reagent is inexpensive, but a laboratory buys hundreds of them, and the range itself is what holds the customer. The dividend is token.
Address:614 MCKINLEY PL N E SUITE 1500, MINNEAPOLIS, MN, 55413, US
Bio-Techne Corp reported revenue of 1.2B $ and net income of 110M $ over the last four quarters. Net margin is 9.05 %. Revenue changed by +0.17 % year over year. Earnings per share are 0.70 $. Market capitalisation is 11.3B $.
TECH has a return on equity of 5.25 %, above the sector median of −41.68 %. Return on assets is 4.30 %, above the sector median of −32.11 %. Operating margin is 12.70 %, above the sector median of −26.84 %.
Bio-Techne Corp pays dividends quarterly: 0.32 $ per share over the past twelve months, a yield of 0.44 %. The latest payment was 0.0800 $, with an ex-dividend date of 24 August 2026.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 111.70 | +1.69 % | 251M |
| BIIBBiogen Inc. | 226.01 | +3.47 % | 224M |
| KODKodiak Sciences Inc | 99.25 | +5.29 % | 214M |
| 72.41 |
| 72.43 |
| 3M |
| 05 October 2026 | 72.41 | 72.61 | 72.38 | 72.58 | 2M |
| 02 October 2026 | 72.44 | 72.47 | 72.38 | 72.40 | 2M |
| 01 October 2026 | 72.50 | 72.54 | 72.38 | 72.40 | 3M |
| 30 September 2026 | 72.38 | 72.55 | 72.33 | 72.47 | 3M |
| 29 September 2026 | 72.36 | 72.50 | 72.36 | 72.38 | 3M |
| 28 September 2026 | 72.58 | 72.65 | 72.49 | 72.51 | 4M |
| 25 September 2026 | 72.59 | 72.64 | 72.56 | 72.61 | 2M |
| 24 September 2026 | 72.54 | 72.63 | 72.51 | 72.57 | 3M |
| 23 September 2026 | 72.50 | 72.64 | 72.48 | 72.52 | 4M |
| 22 September 2026 | 72.52 | 72.69 | 72.46 | 72.55 | 3M |
| 21 September 2026 | 72.50 | 72.54 | 72.44 | 72.47 | 5M |
| 18 September 2026 | 72.41 | 72.44 | 72.26 | 72.37 | 5M |
| 17 September 2026 | 72.36 | 72.48 | 72.28 | 72.41 | 4M |
| 16 September 2026 | 72.35 | 72.37 | 72.22 | 72.33 | 4M |
| 15 September 2026 | 72.28 | 72.39 | 72.21 | 72.34 | 3M |
| 14 September 2026 | 72.21 | 72.30 | 72.17 | 72.27 | 3M |